Share
PrintYardena Samuels, Ph.D.
Investigator, Cancer Genetics Branch
Head, Molecular Cancer Genetics Section
Selected Publications
Samuels-Lev Y, O'Connor DJ, Bergamaschi D., Trigiante G, Hsieh JK, Zhong S, Campargue I., Naumovski L., Crook T., and Lu X. ASPP proteins specifically stimulate the apoptotic function of p53. Molecular Cell, 8:781-94. 2001. [PubMed]
Bergamaschi D, Samuels Y, O'Neil NJ, Trigiante G, Crook T, Hsieh JK, O'Connor DJ, Zhong S, Campargue I, Tomlinson ML, Kuwabara PE, and Lu X. iASPP oncoprotein is a key inhibitor of p53 conserved from worm to human. Nat Genet, 33:162-167. 2003. [PubMed]
Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, Yan H, Gazdar A, Powell SM, Riggins GJ, Willson JK, Markowitz S, Kinzler KW, Vogelstein B, Velculescu VE. High frequency of mutations of the PIK3CA gene in human cancers. Science, 304:554. 2004. [PubMed]
Samuels Y, Diaz LA, Jr., Schmidt-Kittler O, Cummins JM, Delong L, Cheong I, Rago C, Huso DL, Lengauer C, Kinzler KW, Vogelstein B, Velculescu VE. Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell, 7:561-573. 2005. [PubMed]
Parsons DW, Wang TL, Samuels Y, Bardelli A, Cummins JM, DeLong L, Silliman N, Ptak J, Szabo S, Willson JK, Markowitz S, Kinzler KW, Vogelstein B, Lengauer C, Velculescu VE. Colorectal cancer: mutations in a signalling pathway. Nature, 436:792. 2005. [PubMed]
Bergamaschi D, Samuels Y, Zhong S, Lu X. Mdm2 and mdmX prevent ASPP1 and ASPP2 from stimulating p53 without targeting p53 for degradation. Oncogene, 24(23):3836-41. 2005. [PubMed]
Samuels Y, Ericson K. Oncogenic PI3K and its role in cancer. Current Opinion in Oncology Curr Opin Oncol, 18(1):77-82. 2006. [PubMed]
Samuels Y, Diaz LA, Jr., Schmidt-Kittler O, Cummins JM, Delong L, Cheong I, Rago C, Huso DL, Lengauer C, Kinzler KW, Vogelstein B, and Velculescu VE. Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell, 7(6): 561-573. 2006. [PubMed]
Bergamaschi D, Samuels Y, Sullivan A, Gasco M, Syed N, Zvelebil M, Breyssens H, Bisso A, Smith P, Del Sal G, Crook T, Lu X. iASPP preferentially binds the proline rich region of p53 and modulates the apoptotic function of codon 72 polymorphic p53. Nature Genetics, 38(10):1133-1141. 2006. [PubMed]
Huang CH, Mandelker D, Schmidt-Kittler O, Samuels Y, Velculescu VE, Kinzler KW, Vogelstein B, Gabelli SB, and Amzel LM. The Structure of a Human p110α/p85α Complex Elucidates the Effects of Oncogenic PI3Kα Mutations. Science, 318:1744-1748. 2007. [PubMed]
Solomon DA, Kim JS, Cronin JC, Sibenaller Z, Ryken T, Rosenberg SA, Ressom H, Jean W, Bigner D, Yan H, Samuels Y, Waldman T. Mutational inactivation of PTPRD in glioblastoma multiforme and malignant melanoma. Cancer Res, 68:10300-10306. 2008. [PubMed]
Palavalli LH, Prickett TD, Wunderlich JR, Wei X, Burrell AS, Porter-Gill P, Davis S, Wang C, Cronin JC, Agrawal NS, Lin JC, Westbroek W, Hoogstraten-Miller S, Molinolo AA, Fetsch P, et al. Analysis of the matrix metalloproteinase family reveals that MMP8 is often mutated in melanoma. Nat Genet, 41:518-520. 2009. [PubMed]
Prickett TD, Agrawal NS, Wei X, Yates KE, Lin JC, Wunderlich JR, Cronin JC, Cruz P, Rosenberg SA, Samuels Y: Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4. Nat Genet, 41(10):1127-32. 2009. [PubMed]
Wei X, Prickett TD, Viloria CG, Molinolo A, Lin JC, Cardenas-Navia I, Cruz P, Rosenberg SA, Davies MA, Gershenwald JE, Lopez-Otin C, Samuels Y. Mutational and functional analysis reveals ADAMTS18 metalloproteinase as a novel driver in melanoma. Mol Cancer Res, 8:1513-1525. 2010. [PubMed Central]
Wei X, Moncada A, Cal S, Rudloff U, Lin J, NISC Comparative Sequencing Program, Rosenberg S, López-Otín C, Samuels Y. Analysis of the disintegrin-metalloproteinases family reveals ADAM7 and ADAM29 are often mutated in melanoma. Hum Mutat, 32:E2148-2175. 2011. [PubMed]
Wei X, Walia V, Lin JC, Teer JK, Prickett TD, Gartner J, Davis S, Stemke-Hale K, Davies MA, Gershenwald JE, Robinson W, Robinson S, Rosenberg SA, Samuels Y. Exome sequencing identifies GRIN2A as frequently mutated in melanoma. Nat Genet, 43:442-446. 2011. [PubMed Central]
Solomon D, Kim T, Diaz-Martinez L, Fair J, Elkahloun A, Harris B, Toretsky J, Baker S, Rosenberg S, Ladanyi M, Samuels Y, James D, Yu J, Kim J, Waldman T. Mutational inactivation of STAG2 causes aneuploidy in human cancer. Science, 333:1039-1043. 2011. [PubMed]
Prickett T, Wei X, Teer J, Cherukuri P, Lin J, Molinolo A, Rosenberg S, Davies M, Gershenwald J, Stemke-Hale K, Margulies E, Samuels Y. Exon capture analysis of G-Protein Coupled Receptors reveals activating mutations in GRM3 in melanoma. Nature Genetics, 43:1119-1126. 2011. [PubMed]
Last Updated: February 21, 2012
